CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance

The phenomenon of antibiotic resistance (AR) and its increasing global trends and destructive waves concerns patients and the healthcare system. In order to combat AR, it is necessary to explore new strategies when the current antibiotics fail to be effective. Thus, knowing the resistance mechanisms...

Full description

Saved in:
Bibliographic Details
Published in:Drug resistance updates 2023-05, Vol.68, p.100948-100948, Article 100948
Main Authors: Abavisani, Mohammad, Khayami, Reza, Hoseinzadeh, Melika, Kodori, Mansoor, Kesharwani, Prashant, Sahebkar, Amirhossein
Format: Article
Language:English
Subjects:
Antibiotic Resistance
Antibiotics
Antimicrobial resistance
Bacteria - genetics
Bacterial infection
Bacterial Infections - drug therapy
Bacterial Infections - genetics
CRISPR-Cas
CRISPR-Cas Systems - genetics
Drug Resistance, Microbial
Humans
Plasmids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The phenomenon of antibiotic resistance (AR) and its increasing global trends and destructive waves concerns patients and the healthcare system. In order to combat AR, it is necessary to explore new strategies when the current antibiotics fail to be effective. Thus, knowing the resistance mechanisms and appropriate diagnosis of bacterial infections may help enhance the sensitivity and specificity of novel strategies. On the other hand, resistance to antimicrobial compounds can spread from resistant populations to susceptible ones. Antimicrobial resistance genes (ARGs) significantly disseminate AR via horizontal and vertical gene transfer. The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system is a member of the bacterial immune system with the ability to remove the ARGs; therefore, it can be introduced as an effective and innovative strategy in the battle against AR. Here, we reviewed CRISPR-based bacterial diagnosis technologies. Moreover, the strategies to battle AR based on targeting bacterial chromosomes and resistance plasmids using the CRISPR-Cas system have been explained. Besides, we have presented the limitations of CRISPR delivery and potential solutions to help improve the future development of CRISPR-based platforms.
ISSN:1368-7646
1532-2084
DOI:10.1016/j.drup.2023.100948